Pfizer Inc. (PFE)
Pfizer Covid sales boost prompts durability concerns - Bank of America
Pfizer Inc (NYSE:PFE, ETR:PFE)'s reliance on a rebound in demand for Covid-19 products in expectation-beating third-quarter results likely hit sentiment, according to Bank of America analysts. Though the drug maker hiked guidance on better-than-estimated revenue on Tuesday, shares fell by 1.8% following the results.
3 Stocks to Buy Following Robust Quarterly Results
Throughout the Q3 reporting cycle, several companies, including Pfizer, Philip Morris, and Tenet Healthcare, have stolen the spotlight, with each raising guidance.
Here's Why Pfizer (PFE) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Pfizer Stock Tumbled on Tuesday
The specter of an activist investor looms over the company.
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
In a Tuesday interview with CNBC's Jim Cramer, Pfizer CEO Albert Bourla struck a positive tone about activist investor Starboard Value, saying he agreed with some of its criticisms, but maintained that the company is headed in a good direction. "I think we are doing a lot of changes.
Pfizer, Inc. (PFE) Q3 2024 Earnings Call Transcript
Pfizer, Inc. (NYSE:PFE ) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer & SVP Albert Bourla - Chairman & CEO Dave Denton - CFO Mikael Dolsten - Chief Scientific Officer and President of Research & Development Chris Boshoff - EVP & Chief Oncology Officer Alexandre de Germay - EVP & Chief International Commercial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Kripa Devarakonda - Truist Umer Raffat - Evercore Trung Huynh - UBS Louise Chen - Cantor Geoff Meacham - Citi Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets Courtney Breen - Bernstein Steve Scala - TD Cowen Rajesh Kumar - HSBC Akash Tewari - Jefferies Vamil Divan - Guggenheim Securities Dave Risinger - Leerink Partners Chris Schott - JPMorgan Mohit Bansal - Wells Fargo Operator Good day, everyone, and welcome to Pfizer's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded.
Pfizer CEO Defends Record Against Activist Attack
Pfizer shares have performed abysmally in recent years, as the company has failed to win investor confidence ahead of a wave of patent expirations coming by the end of the decade.
Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for the third quarter of 2024 by a large margin. Tafamidis franchise sales were $1.45 billion in Q3 2024, an increase of 9.4% quarter-on-quarter and 62.2% year-on-year. Meanwhile, sales of Padcev, approved for the treatment of urothelial cancer, amounted to $409 million for the three months ended September 30, 2024, an increase of 104.5% year-on-year.
Pfizer's Strong Quarter Bolsters CEO's Comeback Efforts
The pharmaceutical company reported its third consecutive quarter with positive results.
Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor
Shares of Pfizer (PFE) fell Tuesday as a strong earnings report is seen as likely to limit activist investor Starboard Value from driving major changes at the drugmaker.
Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
Pfizer's Q3 earnings smashed analysts' expectations, driven by a significant increase in COVID-related revenues, but the market remains skeptical about long-term growth. Despite strong financials and upgraded 2024 guidance, Pfizer's stock is down 2% in trading today, reflecting concerns that COVID revenue gains are temporary. Non-COVID segments showed mixed results, with underwhelming performance in Primary Care and Oncology, and limited returns from recent M&A activities.
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
